Tina Albertson
No más puestos en curso
Fortuna: 16 919 $ al 31/05/2024
Perfil
Tina Albertson worked as the Medical Director at Seagen Inc. from 2010 to 2015.
She then served as the Vice President-Global Drug Development at Juno Therapeutics, Inc. from 2015 to 2020.
Currently, she is the Chief Medical Officer & Head-Development at Lyell Immunopharma, Inc. since 2020.
Dr. Albertson holds a doctorate degree from Stanford University, the University of Washington, and an undergraduate degree from the University of Oregon.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0.00% | 31/03/2024 | 6 108 ( 0.00% ) | 16 919 $ | 31/05/2024 |
Antiguos cargos conocidos de Tina Albertson.
| Empresas | Cargo | Fin |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Director Técnico/Científico/I+D | 01/11/2023 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/04/2020 |
| SEAGEN INC. | Director Técnico/Científico/I+D | 01/01/2015 |
Formación de Tina Albertson.
| Stanford University | Doctorate Degree |
| University of Oregon | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Tina Albertson
